Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN: 4,369 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
4,369
Total FAERS Reports
446 (10.2%)
Deaths Reported
1,044
Hospitalizations
4,369
As Primary/Secondary Suspect
35
Life-Threatening
22
Disabilities

First Report: 20021001 · Latest Report: 20230601

What Are the Most Common HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN Side Effects?

#1 Most Reported
Sinusitis
436 reports (10.0%)
#2 Most Reported
Headache
375 reports (8.6%)
#3 Most Reported
Fatigue
336 reports (7.7%)

All HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Sinusitis 436 10.0% 6 55
Headache 375 8.6% 6 76
Fatigue 336 7.7% 12 71
Malaise 259 5.9% 19 77
Pneumonia 259 5.9% 35 133
Pyrexia 249 5.7% 23 88
Death 231 5.3% 230 60
Infusion site pain 230 5.3% 6 26
Nausea 223 5.1% 9 54
Covid-19 215 4.9% 58 103
Infusion site erythema 213 4.9% 8 26
Pain 200 4.6% 9 48
Infusion site swelling 194 4.4% 5 25
Infusion site extravasation 185 4.2% 5 30
Nasopharyngitis 176 4.0% 3 23
Infection 168 3.9% 12 46
Inappropriate schedule of product administration 162 3.7% 15 65
Bronchitis 156 3.6% 4 23
Urinary tract infection 150 3.4% 15 52
Dyspnoea 121 2.8% 10 58

Who Reports HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN Side Effects? Age & Gender Data

Gender: 71.6% female, 28.4% male. Average age: 50.8 years. Most reports from: US. View detailed demographics →

Is HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN Getting Safer? Reports by Year

YearReportsDeathsHosp.
2002 1 0 0
2003 1 0 0
2005 1 0 0
2007 1 0 1
2010 1 0 0
2011 1 0 0
2012 2 0 1
2013 4 0 0
2014 39 1 5
2015 339 1 52
2016 294 7 58
2017 156 8 43
2018 141 10 54
2019 150 19 56
2020 272 54 104
2021 223 58 114
2022 202 88 111
2023 50 17 24

View full timeline →

What Is HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN Used For?

IndicationReports
Immunodeficiency common variable 1,598
Primary immunodeficiency syndrome 1,055
Product used for unknown indication 1,006
Immunodeficiency 224
Hypogammaglobulinaemia 162
Selective igg subclass deficiency 136
Secondary immunodeficiency 127
Chronic lymphocytic leukaemia 35
Immune system disorder 35
Off label use 32

HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs Alternatives: Which Is Safer?

HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs HUMAN PAPILLOMAVIRUS QUADRIVALENT VACCINE, RECOMBINANT HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs HUMAN RABIES VIRUS IMMUNE GLOBULIN HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs HUMAN RHO IMMUNE GLOBULIN HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs HUMIRA HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs HUMIRA PEN HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs HYALURONATE HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs HYALURONIC ACID HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs HYALURONIC ACID\LIDOCAINE HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs HYALURONIDASE HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN vs HYALURONIDASE-OCSQ\OCRELIZUMAB

Official FDA Label for HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN

Official prescribing information from the FDA-approved drug label.